These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 21664307

  • 21. The cAMP capture compound mass spectrometry as a novel tool for targeting cAMP-binding proteins: from protein kinase A to potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channels.
    Luo Y, Blex C, Baessler O, Glinski M, Dreger M, Sefkow M, Köster H.
    Mol Cell Proteomics; 2009 Dec; 8(12):2843-56. PubMed ID: 19741253
    [Abstract] [Full Text] [Related]

  • 22. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
    Simara P, Stejskal S, Koutna I, Potesil D, Tesarova L, Potesilova M, Zdrahal Z, Mayer J.
    Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
    [Abstract] [Full Text] [Related]

  • 23. Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple-quadrupole and linear ion trap mass spectrometers.
    Marull M, Rochat B.
    J Mass Spectrom; 2006 Mar; 41(3):390-404. PubMed ID: 16470567
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Transcriptional profiling of the dose response: a more powerful approach for characterizing drug activities.
    Ji RR, de Silva H, Jin Y, Bruccoleri RE, Cao J, He A, Huang W, Kayne PS, Neuhaus IM, Ott KH, Penhallow B, Cockett MI, Neubauer MG, Siemers NO, Ross-Macdonald P.
    PLoS Comput Biol; 2009 Sep; 5(9):e1000512. PubMed ID: 19763178
    [Abstract] [Full Text] [Related]

  • 28. PKC potentiates tyrosine kinase inhibitors STI571 and dasatinib cytotoxic effect.
    Tobío A, Alfonso A, Botana LM.
    Anticancer Res; 2014 Jul; 34(7):3347-56. PubMed ID: 24982339
    [Abstract] [Full Text] [Related]

  • 29. Backbone assignment of the tyrosine kinase Src catalytic domain in complex with imatinib.
    Campos-Olivas R, Marenchino M, Scapozza L, Gervasio FL.
    Biomol NMR Assign; 2011 Oct; 5(2):221-4. PubMed ID: 21523440
    [Abstract] [Full Text] [Related]

  • 30. Profiling of methyltransferases and other S-adenosyl-L-homocysteine-binding Proteins by Capture Compound Mass Spectrometry (CCMS).
    Lenz T, Poot P, Gräbner O, Glinski M, Weinhold E, Dreger M, Köster H.
    J Vis Exp; 2010 Dec 20; (46):. PubMed ID: 21189471
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. In situ kinase profiling reveals functionally relevant properties of native kinases.
    Patricelli MP, Nomanbhoy TK, Wu J, Brown H, Zhou D, Zhang J, Jagannathan S, Aban A, Okerberg E, Herring C, Nordin B, Weissig H, Yang Q, Lee JD, Gray NS, Kozarich JW.
    Chem Biol; 2011 Jun 24; 18(6):699-710. PubMed ID: 21700206
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Targeting Filarial Abl-like Kinases: Orally Available, Food and Drug Administration-Approved Tyrosine Kinase Inhibitors Are Microfilaricidal and Macrofilaricidal.
    O'Connell EM, Bennuru S, Steel C, Dolan MA, Nutman TB.
    J Infect Dis; 2015 Sep 01; 212(5):684-93. PubMed ID: 25657255
    [Abstract] [Full Text] [Related]

  • 39. Dasatinib: BMS 354825.
    Drugs R D; 2006 Sep 01; 7(2):129-32. PubMed ID: 16542059
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.